Cargando…
How selecting best upfront therapy for metastatic disease?—Focus on ROS1-rearranged disease
ROS proto-oncogene 1 (ROS1) rearrangements defines a distinct group of non-small cell lung cancer (NSCLC), mainly represented by younger subjects, never smokers and with adenocarcinoma histology. Fusions involving ROS1 gene are present in 1-2% of lung adenocarcinomas and other solid tumors. Identifi...
Autores principales: | Landi, Lorenza, Cappuzzo, Federico |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7815342/ https://www.ncbi.nlm.nih.gov/pubmed/33489827 http://dx.doi.org/10.21037/tlcr-20-1109 |
Ejemplares similares
-
How to select the best upfront therapy for metastatic disease? Focus on ALK-rearranged non-small cell lung cancer (NSCLC)
por: Xia, Bing, et al.
Publicado: (2020) -
The role of plasma genotyping in ALK- and ROS1-rearranged lung cancer
por: Dagogo-Jack, Ibiayi, et al.
Publicado: (2020) -
Decade in review: a new era for RET-rearranged lung cancers
por: Choudhury, Noura J., et al.
Publicado: (2020) -
Targeting chimeras fusion proteins in non-small cell lung cancer: where are we going?
por: Passiglia, Francesco, et al.
Publicado: (2020) -
How selecting best therapy for metastatic NTRK fusion-positive non-small cell lung cancer?
por: Ekman, Simon
Publicado: (2020)